United Therapeutics (NASDAQ:UTHR) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
United Therapeutics Stock, Up 72% Since August, Nears Buy Point Of Rare Base [Yahoo! Finance]
United Therapeutics: Growing Company With Great Franchise In Pulmonary Diseases [Seeking Alpha]
United Therapeutics (NASDAQ:UTHR) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
United Therapeutics (NASDAQ:UTHR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..